氨甲环酸对中重度贫血产妇产后出血的影响(WOMAN-2):一项国际、随机、双盲、安慰剂对照试验
WOMAN-2是一项在尼日利亚、巴基斯坦、坦桑尼亚和赞比亚34家医院开展的国际随机双盲安慰剂对照试验,纳入产程活跃、血红蛋白<100 g/L的中重度贫血产妇,阴道分娩后断脐15分钟内缓慢静脉注射氨甲环酸1 g或安慰剂。主要终点为随机化后24小时内临床诊断的产后出血。结果显示氨甲环酸组产后出血发生率7.0%(530/7579),安慰剂组6.6%(497/7487),RR 1.05(95%CI 0.94-1.19),未降低产后出血风险;两组均未报告血管闭塞事件,无治疗相关不良事件和治疗相关死亡。
要点
- 中重度贫血(血红蛋白<100 g/L)产妇阴道分娩后断脐15分钟内静脉给予氨甲环酸1 g,产后出血发生率7.0% vs 安慰剂6.6%(RR 1.05,95%CI 0.94-1.19),未降低风险。
- 从开始给药到诊断产后出血的中位时间18.5分钟(IQR 5-58);中度贫血20分钟(8-64),重度贫血13分钟(7-44)。
- 1024例产后出血中有时间数据的358例(35%)在试验治疗尚未完全输注完毕前即被诊断。
- 预设亚组分析(贫血严重程度p=0.44、产前出血p=0.044、产道创伤p=0.37、镇痛使用p=0.37、产后出血基线风险p=0.31)均无强烈证据反对效应同质性。
- 两组均未报告血管闭塞事件(肺栓塞、深静脉血栓、卒中、心肌梗死),无治疗相关不良事件和治疗相关死亡。
适用人群与场景
- 产程活跃、血红蛋白<100 g/L(中度或重度贫血)、经阴道分娩的产妇,年龄14-50岁,来自尼日利亚、巴基斯坦、坦桑尼亚和赞比亚4个国家的34家医院。
诊断标准与关键阈值
- 贫血标准:血红蛋白<100 g/L(中度或重度贫血)。
- 主要终点临床诊断的产后出血:估计失血量>500 mL或任何足以影响血流动力学稳定性的失血量,发生于随机化后24小时内。
处置流程与药物剂量
- 阴道分娩、断脐后15分钟内,缓慢静脉注射(超过10分钟)氨甲环酸1 g或匹配安慰剂。
研究设计与关键结果
- 国际、随机、双盲、安慰剂对照试验,4国34家医院,纳入7580例氨甲环酸组和7488例安慰剂组产妇。
- 主要终点:氨甲环酸组产后出血530/7579(7.0%)vs 安慰剂组497/7487(6.6%),RR 1.05(95%CI 0.94-1.19)。
- 预设亚组效应同质性检验:贫血严重程度p=0.44,产前出血p=0.044,产道创伤p=0.37,镇痛使用p=0.37,产后出血基线风险p=0.31。
- 从开始给药到诊断产后出血的中位时间18.5分钟(IQR 5-58);中度贫血20分钟(8-64),重度贫血13分钟(7-44)。
- 1024例产后出血中有时间数据的358例(35%)在试验治疗完全输注前被诊断。
- 两组均未报告血管闭塞事件(肺栓塞、深静脉血栓、卒中、心肌梗死),无治疗相关不良事件和治疗相关死亡。
证据类型、等级与局限
- 证据类型:国际、随机、双盲、安慰剂对照试验(RCT)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于中重度贫血(血红蛋白<100 g/L)阴道分娩产妇,断脐后15分钟内静脉给予氨甲环酸1 g未能降低临床诊断的产后出血风险(RR 1.05,95%CI 0.94-1.19),作者结论为未降低风险。
- 两组均未报告血管闭塞事件(肺栓塞、深静脉血栓、卒中、心肌梗死),无治疗相关不良事件和治疗相关死亡。
指南或共识出处
- WOMAN-2试验,注册号ISRCTN62396133、NCT03475342、PACTR201909735842379;由Bill & Melinda Gates Foundation和Wellcome Trust资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Tranexamic acid, given within 3 h of birth, reduces bleeding deaths in women with postpartum haemorrhage. We examined whether giving tranexamic acid shortly after birth can prevent postpartum haemorrhage in women with moderate or severe anaemia.
METHODS: This international, randomised, double-blind, placebo-controlled trial was done in 34 hospitals across four countries (Nigeria, Pakistan, Tanzania, and Zambia). We recruited women of any age in active labour with moderate or severe anaemia (haemoglobin <100 g/L). We randomly assigned women (1:1) who had given birth vaginally to receive 1 g of tranexamic acid or matching placebo by slow intravenous injection (over 10 min) within 15 min of the umbilical cord being cut or clamped. Women were randomly assigned by selection of the lowest numbered treatment pack from a box containing 20 packs that were identical apart from the pack number. Participants, care givers, and those assessing outcomes were masked to group assignment. The primary outcome was a clinical diagnosis of primary postpartum haemorrhage, which might be an estimated blood loss of more than 500 mL or any blood loss sufficient to compromise haemodynamic stability within 24 h of randomisation, analysed on an intention-to-treat basis. Safety analyses were performed in all participants included in the intention-to-treat population. This trial was registered on ISRCTN (ISRCTN62396133), ClinicalTrials.gov (NCT03475342), and the Pan African Clinical Trial Registry (PACTR201909735842379) and is closed to recruitment.
FINDINGS: From Aug 24, 2019, to Sept 19, 2023, 16 586 women aged 14-50 years were invited to take part and 1518 were excluded. 7580 women were randomly assigned to receive tranexamic acid and 7488 to receive placebo. Primary outcome data were unavailable for one woman in each group. The median time interval from the start of the administration of the trial treatment to the diagnosis of postpartum haemorrhage was 18·5 min (IQR 5-58); 20 min (8-64) in women with moderate anaemia and 13 min (7-44) in women with severe anaemia. 358 (35%) of 1024 with postpartum haemorrhage for whom time data were available were diagnosed before the trial treatment had been fully administered. Clinically diagnosed postpartum haemorrhage occurred in 530 (7·0%) of 7579 in the tranexamic acid group and in 497 (6·6%) of 7487 in the placebo group (risk ratio [RR] 1·05, 95% CI 0·94-1·19). There was no strong evidence against the null hypothesis of homogeneity of effects for any of the prespecified subgroup analyses: severity of anaemia (p=0·44), antepartum haemorrhage (p=0·044), birth canal trauma (p=0·37), use of pain control (p=0·37), and baseline risk of postpartum haemorrhage (p=0·31). There were no vascular occlusive events (pulmonary embolism, deep vein thrombosis, stroke, and myocardial infarction) reported in either group. There were no adverse events related to the treatment and no treatment-related deaths.
INTERPRETATION: In women with moderate and severe anaemia, giving tranexamic acid within 15 min of the umbilical cord being clamped did not reduce the risk of clinically diagnosed postpartum haemorrhage.
FUNDING: The Bill & Melinda Gates Foundation and the Wellcome Trust.
参考来源
- The effect of tranexamic acid on postpartum bleeding in women with moderate and severe anaemia (WOMAN-2): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2024. PMID: 39461792. doi:10.1016/S0140-6736(24)01749-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。